ArticleBiomolecules & biomedicine2026
Mortality prediction in geriatric ICU patients with pneumonia-related sepsis: APACHE II, NEWS, and serum lactate.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictive Value of SMART-COP for Adverse Outcomes in Older ICU Patients with Community-Acquired Pneumonia: A Comparison with CURB-65, SOFA, and APACHE II.Journal of clinical medicine · 2026Article
- Efficacy and safety of ceftazidime-avibactam in carbapenem-resistant gram-negative bacilli sepsis according to infection site.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis secondary to pneumonia is a prominent cause of intensive care unit (ICU) admissions and mortality among older adults, yet early bedside risk stratification poses significant challenges. This study aimed to evaluate the predictive value of the Acute Physiology and Chronic Health Evaluation II (APACHE II) and the National Early Warning Score (NEWS), both individually and in combination, alongside admission serum lactate levels, for predicting mortality in geriatric ICU patients with pneumonia-related sepsis. In this single-center retrospective cohort study, we analyzed patients aged 65 years and older who were admitted between January 1, 2020, and July 1, 2025. Sepsis was defined according to Sepsis-3 criteria; APACHE II (using the worst values within the first 24 hours) and NEWS (measured at ICU admission) were recorded, along with the first lactate and other biomarkers obtained within the first 24 hours. We assessed mortality predictors using logistic regression and evaluated model discrimination through receiver operating characteristic (ROC) analysis. Among the 179 patients (median age 80), the ICU mortality rate was 64.8%. Non-survivors exhibited significantly higher APACHE II and NEWS scores, as well as elevated lactate and inflammatory markers (all p<0.001). In multivariable analysis, APACHE II (OR 1.130; p<0.001), NEWS (OR 1.239; p=0.003), and a history of stroke (OR 2.856; p=0.041) were identified as independent predictors of mortality, whereas lactate did not demonstrate independent predictive capability. Although lactate improved the discrimination of a baseline clinical-laboratory model (AUC increased from 0.67 to 0.75), it offered no incremental benefit when APACHE II and NEWS were included; the combined APACHE II+NEWS model achieved the highest AUC of 0.85. Exploratory cut-offs identified very high-risk subgroups (APACHE II >21 with NEWS >8 or lactate >2 mmol/L), with mortality rates approximating 86-87%. In conclusion, APACHE II and NEWS are robust early predictors of mortality in geriatric patients with pneumonia-related sepsis, while lactate may assist in early risk stratification but provides limited prognostic value beyond these scoring systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.